JP2022162981A - Vitamin b1-containing oral liquid composition - Google Patents

Abstract

To provide an oral liquid composition containing vitamin B1 or a derivative thereof or salts thereof, the composition showing a reduction in vitamin B1-derived unpleasant odor.SOLUTION: An oral liquid composition contains a vitamin B1, and at least one selected from the group consisting of galangal extract and mango leaf extract .SELECTED DRAWING: None

Description

The present invention relates to oral liquid compositions containing vitamin B1 or its derivatives or salts thereof. More particularly, it relates to an oral liquid composition with reduced unpleasant odors derived from vitamin B1 or its derivatives or salts thereof.

Vitamin B1 or its derivatives or salts thereof (hereinafter also referred to as "vitamin B1s") are known as nutrients necessary for maintaining the functions of the body. It must be taken from quasi-products and food. Vitamin B1 is included in many products, such as oral liquid-type vitamin-containing health supplements that are taken for the purpose of nutritional supplementation during physical fatigue, and soft drinks that can supply nutrients for a day. It contributes to the nutritional supplementation of consumers. On the other hand, vitamin B1s are known to decompose in solution and generate a peculiarly unpleasant odor like rotten eggs, making it difficult to develop products that are easy to take from the standpoint of flavor. rice field.

In order to solve such problems, there is known a method of containing limonene and nootkatone, which are often contained in citrus fruits, to suppress the unpleasant odor peculiar to vitamin B1 (Patent Document 1). There is also known a method of preventing the generation of offensive odor components due to the decomposition of vitamin B1 by adding a black tea extract to a vitamin B1-containing acidic drink composition (Patent Document 2). Since the flavor is limited, versatility is low, and further technical improvement has been required.

Patent No. 5371827 Patent No. 4418702

An object of the present invention is to provide an oral liquid composition containing vitamin B1, a derivative thereof, or a salt thereof, in which unpleasant odors derived from vitamin B1s are reduced.

As a result of intensive studies to solve the above problems, the present inventors have found that, in a composition containing vitamin B1s, an extract of the rhizome of Alpinia galanga L., which is a plant belonging to the genus Gingerbaceae of the Zingiberaceae family, or The present inventors have found that the unpleasant odor derived from vitamin B1s can be reduced by blending an extract of mango (Mangifera indica L.) leaves, which is a plant belonging to the genus Mango of the Anacardiaceae family.
That is, the present invention is as follows.
(1) an oral liquid composition characterized by containing one or more selected from the group consisting of vitamin B1s and galangal extract and mango leaf extract;
(2) The oral liquid composition according to (1), wherein the concentration of vitamin B1s is 0.0001 to 0.05% by mass,
(3) The oral liquid composition according to (1) or (2), wherein the concentration of the galangal extract is 0.001 to 10% by mass as a dry solid content,
(4) The oral liquid composition according to any one of (1) to (3), wherein the concentration of mangiferin is 0.001 to 10% by mass.
(5) The oral liquid composition according to any one of (1) to (4), which has a pH of 2.0 to 7.0,
(6) the oral liquid composition according to any one of (1) to (5), wherein the oral liquid composition is a liquid drink;
(7) The oral liquid according to any one of (1) to (6), wherein the content of the galangal extract as a dry solid content equivalent to 1 part by mass of vitamin B1 is 0.02 to 100000 parts by mass. Composition,
(8) The oral liquid composition according to any one of (1) to (7), wherein the content of mangiferin per 1 part by mass of vitamin B1 is 0.02 to 100000 parts by mass,
(9) A method of suppressing the unpleasant odor of vitamin B1s in an oral liquid composition containing vitamins B1 by adding galangal extract and/or mango leaf extract.

INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an oral liquid composition containing vitamin B1s in which unpleasant odors derived from vitamins B1s are reduced.

In the present invention, the vitamin B1s refer to vitamin B1 or derivatives thereof or salts thereof, which are usually edible. Mention may be made of benfotiamine, sicotiamine, octotiamine, prosultiamine and salts thereof. Salts used in the present invention include nitrates, hydrochlorides, sulfates and the like, preferably nitrates or hydrochlorides.

The content of vitamin B1s in the present invention is preferably 0.0001% by mass to 0.05% by mass, 0.0005% by mass to 0.05% by mass, and 0.0005% by mass in the oral liquid composition of the present invention. % to 0.02% by mass, 0.001% to 0.02% by mass, and 0.001% by mass to 0.01% by mass are more preferable in the order of description, and 0.001% by mass to 0.005% by mass are Especially preferred.

The galangal extract in the present invention refers to the rhizome of Alpinia galanga L. (Alpinia galanga L.), which is a plant belonging to the genus Zingiberaceae (Alpinia galanga L.) (also known as galanga, nankyo, etc.). It can be obtained by extraction after crushing, pulverizing, or the like. That is, the galangal extract in the present invention is an extract of galangal rhizomes. Galangal is different from black ginger, which is a plant belonging to the genus Curcuma of the family Zingiberaceae, and turmeric, which is a plant of the genus Curcuma of the family Zingiberaceae.

The extraction treatment method is not particularly limited, and for example, a known extraction method such as a stirring/shaking/immersion extraction method using an organic solvent such as ethanol, water, or a mixture thereof, or a vacuum steam distillation extraction method may be used. If necessary, centrifugation, enzymatic treatment (treatment with an enzymatic agent based on koji mold or black koji mold), column or filtration (filtration with a strainer mesh, membrane filter, etc.) may be used to remove insoluble matter. . The galangal extract in the present invention preferably uses water and/or alcohol as an extraction solvent, more preferably ethanol as the alcohol, and particularly preferably water alone. The extract obtained by extraction as described above may be used in a liquid state, or may be dried and used in a powder state. Biolife's enXtra ^™ , etc.) may also be used.

The content of the galangal extract in the present invention is preferably 0.001% by mass to 10% by mass, preferably 0.001% by mass to 1%, in the oral liquid composition of the present invention, as a dry solid content equivalent of the galangal extract. % by mass, 0.005% by mass to 1% by mass, 0.005% by mass to 0.6% by mass, 0.01% by mass to 0.6% by mass, 0.02% by mass to 0.6% by mass, 0 0.03 wt% to 0.6 wt%, 0.03 wt% to 0.45 wt%, 0.04 wt% to 0.45 wt%, 0.05 wt% to 0.45 wt%, 0.05 % by mass to 0.3% by mass are more preferred in the stated order, and 0.06% by mass to 0.3% by mass are particularly preferred. In the present invention, the "dry solid content equivalent amount" refers to the amount converted to the amount of the portion excluding water. Moisture content can be measured using a conventionally known heat drying method, Karl Fischer method, or the like.

In addition, the content of the galangal extract in the present invention is preferably 0.01% by mass to 100% by mass, preferably 0.01% by mass to 10% by mass, in the oral liquid composition of the present invention, in terms of galangal rhizome. , 0.05% to 10% by weight, 0.05% to 6% by weight, 0.1% to 6% by weight, 0.2% to 6% by weight, 0.3% to 6% by weight , 0.3% by mass to 4.5% by mass, 0.4% by mass to 4.5% by mass, 0.5% by mass to 4.5% by mass, and 0.5% by mass to 3% by mass in the order of description More preferably, 0.6% by mass to 3% by mass is particularly preferable.

The oral intake of the galangal extract in the present invention is preferably 10 mg to 1000 mg, preferably 10 mg to 500 mg, 50 mg, in the oral liquid composition of the present invention, as a dry solid content equivalent of the galangal extract. ~500 mg, 50 mg to 400 mg, 50 mg to 300 mg, and 100 mg to 300 mg are more preferred in the stated order, and 150 mg to 300 mg are particularly preferred. The term "a dose per oral intake" in the present invention refers to the amount of the oral liquid composition of the present invention taken at one time, more It indicates the amount to be ingested for a period of time, and is, for example, 50 mL to 500 mL.

In the oral liquid composition of the present invention, the mass ratio of the vitamin B1s and the dry solid content equivalent of the galangal extract, that is, the content of the galangal extract as the dry solid content equivalent to 1 part by mass of the vitamin B1s is preferably 0.02 parts by mass to 100000 parts by mass, preferably 0.02 parts by mass to 6000 parts by mass, 0.4 parts by mass to 6000 parts by mass, and 0.4 parts by mass to 3000 parts by mass in the order described, 1.2 parts by mass to 3000 parts by mass are particularly preferred.

In the oral liquid composition of the present invention, the mass ratio of the vitamin B1s and the galangal extract in terms of galangal rhizomes, that is, the amount of the galangal extract in terms of galangal rhizomes relative to 1 part by mass of the vitamin B1s is 0.2 mass. Parts to 1,000,000 parts by weight are preferred, 0.2 parts to 60,000 parts by weight, 4 parts to 60,000 parts by weight, and 4 parts to 30,000 parts by weight are more preferred in the order listed, and 12 parts to 30,000 parts by weight are particularly preferred. .

The mango leaf extract in the present invention is obtained by extracting the leaves of mangifera indica L., which is a plant belonging to the genus Mangifera of the family Anacardiaceae, as they are, or after drying, crushing, pulverizing, etc., if necessary. can get.
The extraction treatment method is not particularly limited, and for example, a known extraction method such as a stirring/shaking/immersion extraction method using an organic solvent such as ethanol, water, or a mixture thereof, or a vacuum steam distillation extraction method may be used. If necessary, centrifugation, enzymatic treatment (treatment with an enzymatic agent based on koji mold or black koji mold), column or filtration (filtration with a strainer mesh, membrane filter, etc.) may be used to remove insoluble matter. . As the mango leaf extract in the present invention, commercially available products (for example, Zynamite manufactured by Nektium, etc.) may be used.

In addition, mango leaf extract usually contains mangiferin (1,3,6,7-tetrahydroxyxanthone C2-β-D-glucoside), and the amount of mangiferin in the oral liquid composition is It may also be used as an indicator of the content of mango leaf extract in the product. Mangiferin can be quantified using the method described in the section of Byakkokaninjinto extract in the Japanese Pharmacopoeia 18th Edition. The amount of mangiferin in the oral liquid composition of the present invention is preferably 0.001% by mass to 10% by mass, 0.0024% by mass to 1% by mass, 0.012% by mass to 0.72% by mass, and 0.036% by mass. % by mass to 0.36% by mass are more preferred in the stated order, and 0.06% by mass to 0.18% are particularly preferred.

In the oral liquid composition of the present invention, the mass ratio of the vitamin B1s and the amount of mangiferin, that is, the amount of mangiferin to 1 part by mass of the vitamins B1 is preferably 0.02 parts by mass to 100000 parts by mass, and 0.12 parts by mass. Parts to 10000 parts by weight, 0.48 parts to 7200 parts by weight are more preferred in the order listed, and 3 parts to 1440 parts by weight are particularly preferred.
The mango leaf extract per oral intake of the present invention is preferably 0.5 mg to 50000 mg, preferably 5 mg to 5000 mg, in the oral liquid composition of the present invention as the amount of mangiferin in the mango leaf extract. , 12 mg to 1000 mg, and 12 mg to 360 mg are more preferred in the stated order, and 60 mg to 360 mg are particularly preferred.

The pH of the oral liquid composition of the present invention is not particularly limited, but is preferably 2.0 to 7.0, more preferably 2.0 to 4.5, more preferably 2.0 to 4.0 from the viewpoint of being suitable for drinking. is more preferred, 2.0 to 3.9 is even more preferred, and 3.0 to 3.9 is particularly preferred.

The pH of the oral liquid composition of the present invention can be adjusted using commonly used pH adjusters. Specific pH adjusters include organic acids such as citric acid, malic acid, tartaric acid, succinic acid, lactic acid, acetic acid, maleic acid, gluconic acid, aspartic acid, adipic acid, glutamic acid, and fumaric acid, salts thereof, and hydrochloric acid. and inorganic bases such as sodium hydroxide. Preferred pH adjusters are citric acid, salts of citric acid, hydrochloric acid, and sodium hydroxide.

In addition, the oral liquid composition of the present invention may contain vitamins other than vitamin B1, minerals, amino acids or salts thereof, crude drugs, crude drug extracts, as long as the effects of the present invention are not impaired. , royal jelly, caffeine, etc. can be appropriately added.

Furthermore, the oral liquid composition of the present invention may contain antioxidants, coloring agents, flavoring agents, corrigents, surfactants, thickeners, stabilizers, preservatives, and sweeteners, as long as they do not impair the effects of the present invention. , an acidulant, etc., can be added as appropriate.

The oral liquid composition in the present invention is not particularly limited as long as it is a liquid composition that can be taken orally. ). Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Foods include soft drinks, carbonated drinks, sports/functional drinks, non-alcoholic drinks, milk drinks, tea drinks, coffee drinks, fruit/vegetable drinks, jelly drinks and the like.

The oral liquid composition of the present invention can be produced by a conventionally known method. For example, galangal extract or mango leaf extract and vitamin B1 are added to water, and if desired, the other components described above are added and dissolved, and water is added to adjust the volume. It can be provided as an easy-to-carry oral liquid composition by subjecting it to pH adjustment and heat sterilization as necessary and filling it in a container.

When the oral liquid composition of the present invention is a carbonated drink, for example, galangal extract or mango leaf extract and vitamin B1 are added to water, and if desired, the other ingredients described above are added and dissolved. , to prepare the beverage concentrate. After adjusting the pH and sterilizing by heating as necessary, after cooling, carbon dioxide is injected (carbonation), filled in a container, and sterilized as appropriate. The gas volume is preferably between 0.5 and 4.0. The gas volume is the volume ratio of carbon dioxide dissolved in liquid 1 as a solvent under standard conditions (1 atm, 20° C.). There are a premix method and a postmix method for producing carbonated beverages, and either method may be employed in the present invention.

EXAMPLES The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to these examples. As vitamin B1s, commercial products such as thiamine nitrate manufactured by DSM, thiamine disulfide manufactured by Tokyo Chemical Industry, fursultiamine hydrochloride manufactured by Watanabe Chemical, and benfotiamine manufactured by Tokyo Chemical Industry were used. As the mango leaf extract, Zynamite manufactured by Nektium was used in the following examples and comparative examples.
(Extraction Examples 1 and 2, Examples 1 to 10, Comparative Examples 1 to 10)

Preparation of galangal extract:
[Extraction Example 1: Hereinafter, referred to as galangal extract A in the present invention]
Galangal rhizomes were extracted with hot water and concentrated under reduced pressure using a conventional method to obtain a dry powdery (solid) extract of 1/10 of the mass of galangal rhizomes.
[Extraction Example 2: Hereinafter, referred to as galangal extract B in the present invention]
Galangal rhizomes were extracted with hot water, and subjected to enzymatic treatment, filtration, and concentration under reduced pressure using conventional methods to obtain a liquid (liquid) extract of Brix 15 (soluble solid content: 15%).
In the tables of test examples, both galangal extracts A and B are described in terms of galangal dry solid content.

Preparation of oral liquid composition:
Oral liquid compositions were prepared according to the formulations shown in Tables 2-7 below and the following method. First, thiamine nitrate, thiamine disulfide, fursultiamine hydrochloride, or benfotiamine was added to purified water and dissolved. Purified water was preheated to 70° C. depending on the solubility of vitamin B1 before use. After that, galangal extract A, galangal extract B, or mango leaf extract was added and stirred well. After stirring, the pH was adjusted using hydrochloric acid and sodium hydroxide solution, and purified water was added to make up the total volume to obtain oral liquid compositions (Examples 1 to 10). Oral liquid compositions without addition of galangal extract A, galangal extract B, or mango leaf extract were used as comparative examples (Comparative Examples 1-10).

The resulting oral liquid composition was passed through a screw tube no. 6 (manufactured by Maruem Co., Ltd.) was filled with 30 ml and sterilized at 80° C. for 25 minutes. After sterilization, the prepared oral liquid composition was stored at 65°C for 7 days.

Evaluation of unpleasant odor derived from vitamin B1:
As described above, the oral liquid composition stored at 65° C. for 7 days was sniffed, and the degree of reduction in unpleasant odor was evaluated according to the criteria shown in Table 1.

As is clear from Tables 2 to 7, the compositions containing vitamin B1s and galangal extract or mango leaf extract show an effect of reducing unpleasant odors derived from vitamins B1s compared to the comparative examples. rice field.

(Examples 11 and 12)
Liquid beverages and carbonated beverages were prepared according to the formulations listed in Table 8 and the following methods.

Preparation of liquid beverages:
Ingredients other than sodium riboflavin 5′-phosphate and sodium benzoate were added and dissolved in about 50% of the total amount of water. Separately, about 10% of the total amount of sodium riboflavin 5′-phosphate and sodium benzoate were added and dissolved in water at 70° C., and the mixture was thoroughly stirred. After stirring, trisodium citrate was used to adjust the pH, and purified water was added to make up the total volume to obtain an oral liquid composition (Example 11). The obtained oral liquid composition was filled in a 100 ml tea bottle, sealed, and then sterilized at 80° C. for 25 minutes. After sterilization, the prepared oral liquid composition was stored at 65°C for 7 days. Similar to Examples 1 to 10 and Comparative Examples 1 to 10, the unpleasant odor derived from vitamin B1 was evaluated according to the evaluation criteria shown in Table 1.

Preparation of carbonated drinks:
Ingredients other than sodium riboflavin 5′-phosphate and sodium benzoate were added and dissolved in about 10% of the total amount of water. Separately, about 2.5% of the total amount of sodium riboflavin 5′-phosphate and sodium benzoate were added and dissolved in water at 70° C., and the mixture was thoroughly stirred. After stirring, the pH was adjusted with trisodium citrate and water was added to 25% of the total volume to prepare a beverage concentrate. This undiluted beverage was sterilized at 80° C. for 25 minutes, carbonated water was added to make up the total volume, and 250 ml was filled in an aluminum can (Example 12). After filling, the prepared oral liquid composition was stored at 65°C for 7 days. Similar to Examples 1 to 10 and Comparative Examples 1 to 10, the unpleasant odor derived from vitamin B1 was evaluated according to the evaluation criteria shown in Table 1.

As is clear from Table 8, in Examples 11 and 12, it was confirmed that the unpleasant odor derived from vitamin B1 was slightly perceived.

INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to suppress the unpleasant odor when a galangal extract and/or mango leaf extract and vitamin B1 are mixed in an oral liquid composition. The art is expected to provide oral liquid compositions that are highly flavored and highly marketable.

Claims (9)

An oral liquid composition characterized by containing one or more selected from the group consisting of vitamin B1s and galangal extract and mango leaf extract. The oral liquid composition according to claim 1, wherein the concentration of vitamin B1s is 0.0001 to 0.05% by mass. 3. The oral liquid composition according to claim 1 or 2, wherein the concentration of the galangal extract is 0.001 to 10% by mass in terms of dry solid content. The oral liquid composition according to any one of claims 1 to 3, wherein the concentration of mangiferin is 0.001 to 10% by mass. The oral liquid composition according to any one of claims 1 to 4, which has a pH of 2.0 to 7.0. Oral liquid composition according to any one of claims 1 to 5, wherein the oral liquid composition is a liquid drink. The oral liquid composition according to any one of claims 1 to 6, wherein the content of the galangal extract in terms of dry solid content per 1 part by mass of vitamin B1 is 0.02 to 100000 parts by mass. The oral liquid composition according to any one of claims 1 to 7, wherein the content of mangiferin per 1 part by mass of vitamin B1 is 0.02 to 100000 parts by mass. A method for suppressing the unpleasant odor of vitamin B1s in a vitamin B1s-containing oral liquid composition by incorporating a galangal extract and/or a mango leaf extract.